Eledon Pharmaceuticals, Inc.: insider trades · United States · SEC (Form 4)

About Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company listed on the Nasdaq Capital Market under the ticker ELDN in the United States. From an international equity perspective, it is a development-stage immunology company rather than a commercial drugmaker, so the investment case is driven primarily by clinical data, regulatory milestones, and access to capital. The company is headquartered in Irvine, California, with research and development operations in Burlington, Massachusetts. Its corporate history dates back to 2004, when it was originally incorporated as Tokai Pharmaceuticals, Inc.; it later became Novus Therapeutics in 2017 and adopted the Eledon Pharmaceuticals name in 2021. ([ir.eledon.com](https://ir.eledon.com/resources/investor-faqs)) Eledon’s lead program is tegoprubart, an IgG1 anti-CD40L antibody designed to modulate the immune response and help prevent transplant rejection. The company positions tegoprubart as a next-generation immunosuppressive therapy with potential across multiple transplantation settings, including kidney, liver, and islet transplantation, and it also references xenotransplantation as an area of interest. Eledon’s scientific strategy is focused on the CD40L pathway, a biologically validated target with broad therapeutic potential, while the company has also maintained an exploration path in amyotrophic lateral sclerosis (ALS). In practical terms, however, tegoprubart remains the value driver and the central pipeline asset. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1404281/000119312526116164/eldn-20251231.htm)) Competitive positioning should be viewed through the lens of a niche biotech challenger. Eledon does not have the scale, manufacturing footprint, or marketed-product diversification of large pharmaceutical peers. Instead, it is aiming to differentiate through data quality: tolerability, immunosuppressive efficacy, and the possibility of enabling transplant outcomes with fewer complications than standard regimens. That makes the company highly dependent on trial execution, regulatory alignment, and capital-market conditions. SEC filings also underscore the typical biotech risks: a short operating history, recurring operating losses, and ongoing reliance on external financing to fund development. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1404281/000119312526116164/eldn-20251231.htm?utm_source=openai)) Recent developments have been important. In March 2026, Eledon announced that tegoprubart received FDA Orphan Drug designation for the prevention of allograft rejection in liver transplantation, a meaningful regulatory signal for a small biotech. In May 2026, the company reported first-quarter 2026 operating results and highlighted additional data updates in kidney and islet cell transplantation, including updated progress in a type 1 diabetes islet-transplant study. Financially, Eledon remains in a cash-burn phase and has continued to raise capital, including a public offering in November 2025, which is consistent with the funding profile of a clinical-stage biotechnology company. ([ir.eledon.com](https://ir.eledon.com/news-releases/news-release-details/eledon-pharmaceuticals-reports-fourth-quarter-and-full-year-2025?utm_source=openai)) For investors, Eledon is best understood as a Nasdaq-listed United States biotech with a concentrated pipeline, high optionality, and high risk. The stock’s medium-term performance is likely to depend on tegoprubart’s clinical readouts, regulatory progress, and the company’s ability to finance development without excessive dilution. ([ir.eledon.com](https://ir.eledon.com/resources/investor-faqs))